Business Standard

Torrent Pharma acquires four therapy segment brands from Dr Reddy's

Styptovit-E, a gynaecology product, has an estimated market size of roughly Rs 500 crore, according to data from AIOCD, a pharmaceutical market research company

Pharma Sector, Pharma Companies
Premium

Vinay Umarji Ahmedabad
Ahmedabad-based Torrent Pharmaceuticals said on Thursday it has entered into an agreement to acquire four brands from Dr Reddy's Laboratories Ltd. (DRL). 'Styptovit-E', 'Finast', 'Finast-T', and 'Dynapress' will strengthen Torrent’s presence in the therapy segment.

Styptovit-E, a gynaecology product, has an estimated market size of roughly Rs 500 crore, according to data from AIOCD, a pharmaceutical market research company.

'Finast', 'Finast-T', and 'Dynapress' are used in the treatment of Benign Prostatic Hyperplasia (BPH) and they will aid Torrent's presence in the urology therapy.

The terms of the definitive agreement mandate that Torrent Pharma will take over the manufacturing, marketing, and

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: May 26 2022 | 11:41 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com